Arrays will be used by GSK to profile its kinase hits in-house.
Procognia entered into a collaboration with GlaxoSmithKline to explore the use of Procognia’s protein function arrays within the GSK drug development processes in combination with GSK’s fluorescently-labeled, broad-specificity kinase inhibitors.
Under the collaboration, Procognia will be supplying arrays, which contain over 300 functional human kinases, to GSK to enable it to profile its kinase hits in-house. The arrays allow researchers to profile many kinases in a single parallel experiment where previously many separate assays were required.
In addition, Procognia and GSK will work together to assess where Procognia’s protein array technology can be integrated into GSK’s screening process.
Overexpression and misregulation of protein kinases are implicated in a wide variety of diseases. As a result, researchers are developing drugs that alter the activity of targeted kinases in areas such as cancer, inflammation, heart disease, and neuro-degenerative diseases. Across the industry, 30% of all drug discovery efforts are now focused on targeting protein kinases.